Site search

Clear filter
2991 results for '' found
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin [NKTR-358] Monotherapy in the Treatment of Patients = 12 Years of
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin [NKTR-358] Monotherapy in the Treatment of Patients = 12 Years of
/
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persist
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persist
/
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered A
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered A
/
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium [177Lu] vipivotide tetraxetan [AAA617] in combination with an androgen receptor pathway inhibitor
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium [177Lu] vipivotide tetraxetan [AAA617] in combination with an androgen receptor pathway inhibitor
/
A Phase 1/2 Study of CLIO-8221 in Patients with Advanced Solid Tumors (NCT07300943)
A Phase 1/2 Study of CLIO-8221 in Patients with Advanced Solid Tumors (NCT07300943)
/
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma [DAWN-303] (NCT07522073)
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma [DAWN-303] (NCT07522073)
/
The effect of retrograde autologous priming on transfusion requirements after cardiac surgery [TheRAPy]: a multiple period vanguard cluster crossover trial – Australian arm (Trial Not Registered)
The effect of retrograde autologous priming on transfusion requirements after cardiac surgery [TheRAPy]: a multiple period vanguard cluster crossover trial – Australian arm (Trial Not Registered)
/
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s
A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer’s
/
A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma [PDAC].
A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma [PDAC].
/
Clinical Effectiveness of Ripretinib in Gastrointestinal Stromal Tumor [GIST]: Real-world Experience in Australia (Trial Not Registered)
Clinical Effectiveness of Ripretinib in Gastrointestinal Stromal Tumor [GIST]: Real-world Experience in Australia (Trial Not Registered)
/
1 2 3 4